Last updated: April 27, 2026
What does Singapore patent SG171649 cover, and what does its claims set imply for the patent landscape?
What is SG171649 and what is its procedural status in Singapore?
The provided request does not include the patent document text, bibliographic data, or claim set for Singapore patent SG171649. Without the underlying publication/filing document (e.g., Singapore publication number, title, assignee, publication date, priority documents, and the full claim text), a complete and accurate scope-and-claims analysis and a defensible Singapore-focused landscape map cannot be produced.
What is the claim scope of SG171649?
A claims-level scope analysis requires the exact independent and dependent claims, their claim numbering, defined terms, and any prosecution or restriction language present in the granted or published version in Singapore. That information is not present in the request, so no accurate claim chart, term construction, or “what is covered vs. not covered” breakdown can be generated.
How broad is the protection SG171649 appears to seek (by structure and dependencies)?
A meaningful breadth assessment depends on claim structure (composition vs. method vs. use; Markush breadth; salts/polymorphs; dosage ranges; process parameters), dependency depth, and whether claims are tied to specific examples or generic formulae. The SG171649 claim set is not supplied, so no valid breadth scoring (for example, “composition of matter” vs. “therapeutic method” vs. “formulation” vs. “second medical use”) can be performed.
What is the likely commercial “design-around” risk based on claim elements?
Risk mapping relies on claim element inventory (active ingredient definition, specific formulation excipients, particle size or solid form parameters, route of administration, treatment regimen, biomarkers, patient subsets, and intended therapeutic indication). These elements are not available from the request, so no credible design-around pathways can be identified for either generics or follow-on innovators.
What does SG171649 imply about related families and priority sources?
Landscape analysis in Singapore hinges on:
- the family’s upstream priority (often PCT/WO) and whether SG claims track those,
- whether Singapore includes salt/polymorph, second medical use, and method-of-treatment claims,
- whether there are co-existing grants or withdrawals in Singapore,
- whether other jurisdictions (EP/US/WO/CN/JP) show overlapping claim themes that affect enforcement likelihood.
None of this family metadata is present for SG171649 in the request.
What does the SG patent landscape look like around SG171649 (closest peers, overlap, and blocking positions)?
A landscape map requires at least:
- assignee and invention title,
- exact therapeutic area and active ingredient,
- publication and priority dates,
- claim-level overlap with the nearest Singapore publications/registrations on the same molecule and regimen.
Those anchor facts are not provided for SG171649, so a non-speculative landscape cannot be produced.
Can this be translated into an actionable freedom-to-operate view for Singapore?
Freedom-to-operate (FTO) for Singapore depends on the enforceable claim set status (published vs. granted), expiry or adjustment, and whether any other Singapore rights in force cover the intended product (drug substance, salt/form, formulation, dosing schedule, and indication). Without claim text and bibliographic status, any FTO view would be fabricated.
Key Takeaways
- A complete and accurate analysis of scope, claims, and the Singapore patent landscape for SG171649 cannot be produced from the provided information.
- Claim-level scope, breadth, and design-around risk require the exact claim text and bibliographic status of SG171649 in Singapore.
- Landscape mapping requires family metadata and Singapore-inforce screening, which are not provided.
FAQs
-
What inputs are required to analyze SG171649 scope and claims?
The SG171649 publication/grant text (including all claims) and bibliographic details (title, assignee, dates, status).
-
Can a patent landscape be built without the active ingredient and priority information?
No. Landscape mapping depends on molecule/regimen identity and priority linkage.
-
Is it enough to rely on an international (WO/EP/US) family for Singapore claim scope?
No. Singapore claim sets can differ, and the enforceable claim set is the Singapore document.
-
What determines whether SG171649 blocks generics in Singapore?
The independent and dependent claims’ elements covering the generic’s intended product or method, plus enforceable status and expiry.
-
How are design-around options identified for Singapore drug patents?
By enumerating claim elements (substance/formulation/regimen/indication) and testing whether an alternative still reads on each limitation.
References (APA)
No sources were provided or cited because SG171649’s Singapore patent document text and bibliographic data are not included in the request.
